Clinical Trial

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-05.
Trial Details
NCT Number NCT07107204
Lead Sponsor Biotroy Therapeutics
Conditions Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
Enrollment 116 participants
Start Date 2025-10
Primary Completion 2028-01 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-17